Established in 2020, the Melbourne ME/CFS Collaboration is directed by Christopher W. Armstrong, PhD.
The Melbourne ME/CFS Collaboration seeks to characterize the unifying biological pathways of ME/CFS that relate to the shared disease experience between patients while also understanding each patients unique biology that create variation in disease experience and severity.
Chris Armstrong, PhD, is most well known for his research using metabolomics to observe biochemical alterations in ME/CFS patients. He began his work in this field at the University of Melbourne, beginning a PhD project to apply metabolomics to study Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) and published his first ME/CFS metabolomics study on blood and urine in 2015.
Open Medicine Foundation is excited to announce that our Science Liaison, Christopher Armstrong, PhD has received a grant of $784,000 for ME / CFS research from the
To carry out these ambitious projects, Dr. Armstrong is establishing networks and collaborations extending to USA, UK, Sweden, and other Australian institutions.
Christopher Armstrong, PhD
Paul Gooley, PhD
Neil McGregor, PhD
David Ascher, PhD
Elisha Josev, PhD
Sarah Knight, PhD
Adam Scheinberg, MD
David Stroud, PhD
Ronald Davis, PhD
Robert Phair, PhD
Laurel Crosby, PhD
Amit Saha, PhD
Mike Snyder, PhD
Jonas Bergquist, MD, PhD
Ronald Tompkins, MD, ScD
Wenzhong Xiao, PhD
Michael VanElzakker, PhD
Alain Moreau, PhD
UC San Diego, USA
Robert Naviaux, MD, PhD
Jarred Younger, PhD
Jo Cambridge, PhD
Sarah Annesley, PhD
Paul Fisher, PhD
Averting a second pandemic:
Open Medicine Foundation leads groundbreaking international study of
Long COVID’s conversion to ME/CFS
AGOURA HILLS, CALIF. — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome — to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.
Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”
OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.
The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.
In a significant percentage of patients, infections preceded their development of ME/CFS. For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.
The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS. Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.
About Open Medicine Foundation
Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.
Heather Ah San
Development and Communications Manager